International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA represents research-based pharmaceutical companies and associations across the globe. Research-based pharmaceutical companies make a unique contribution to global health as innovators of lifesaving and life-changing medicines and vaccines, which improved millions of lives around the world. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Global Health Progress
To drive new and existing collaborations to support the Sustainable Development Goals, IFPMA has launched Global Health Progress - a knowledge hub highlighting over 250 collaborations between the innovative biopharmaceutical industry and more than 1200 partners to support the SDGs.
The Access Accelerated initiative is a partnership of over 20 biopharmaceutical companies developing innovative and sustainable solutions to improve access to non-communicable disease treatment and care in low- and middle income countries. Access Accelerated partners with the World Bank and the City Cancer Challenge (CCAN) to help address the full spectrum of access barriers to NCD medicines.
IFPMA is a partner of Fight the Fakes, a multi-stakeholders campaign that aims to raise awareness about the dangers of falsified medicines. IFPMA hosts the Secretariat of the AMR Industry Alliance, a coalition of over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. To support the next generation of public health leaders in Africa, IFPMA, together with the Centre on Global Health Security at Chatham House, established the African Global Health Leaders Fellowship.
Since ethical business practices are at the heart of patient-centered healthcare, IFPMA holds since 2018 the industry Co-Chair of the Business Ethics for APEC SMEs Initiative, the world’s largest public-private partnership to strengthen ethical business practices in the biopharmaceutical sector. One of the Initiative’s goals is to introduce national ethics accords between industry and non-industry health bodies, the so called Consensus Frameworks.